| Code | CSB-RA025141MB8HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to MG-014, targeting thymic stromal lymphopoietin (TSLP), an epithelial cell-derived cytokine that plays a critical role in initiating and sustaining allergic inflammatory responses. TSLP functions as a master regulator of type 2 immunity by activating dendritic cells, which subsequently prime naive T cells toward a Th2 phenotype. This cytokine is strongly implicated in the pathogenesis of allergic diseases including asthma, atopic dermatitis, eosinophilic esophagitis, and chronic obstructive pulmonary disease, where elevated TSLP expression correlates with disease severity and airway inflammation.
MG-014 represents a therapeutic antibody developed to neutralize TSLP activity and has been investigated in clinical studies for allergic conditions. This biosimilar reagent provides researchers with a valuable tool for investigating TSLP-mediated signaling pathways, studying the mechanisms underlying allergic inflammation, exploring epithelial-immune cell interactions, and evaluating potential therapeutic interventions in preclinical disease models. The antibody enables detailed examination of TSLP's role in both physiological and pathological immune responses.
There are currently no reviews for this product.